Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

BUY
$6.7 - $24.21 $126,596 - $457,447
18,895 Added 3.04%
641,249 $15.5 Million
Q4 2022

Feb 13, 2023

BUY
$4.52 - $10.57 $258,959 - $605,576
57,292 Added 10.14%
622,354 $6.58 Million
Q3 2022

Nov 14, 2022

BUY
$3.43 - $5.62 $164,399 - $269,366
47,930 Added 9.27%
565,062 $2.54 Million
Q2 2022

Aug 12, 2022

SELL
$3.65 - $7.3 $16,114 - $32,229
-4,415 Reduced 0.85%
517,132 $2.07 Million
Q1 2022

May 13, 2022

SELL
$3.4 - $7.88 $62,138 - $144,014
-18,276 Reduced 3.39%
521,547 $3.82 Million
Q4 2021

Feb 08, 2022

SELL
$5.59 - $7.39 $147,475 - $194,962
-26,382 Reduced 4.66%
539,823 $3.03 Million
Q3 2021

Nov 15, 2021

SELL
$5.66 - $8.33 $36,212 - $53,295
-6,398 Reduced 1.12%
566,205 $3.62 Million
Q2 2021

Aug 13, 2021

SELL
$6.71 - $11.04 $167,602 - $275,757
-24,978 Reduced 4.18%
572,603 $4.83 Million
Q1 2021

May 12, 2021

BUY
$10.12 - $19.45 $197,896 - $380,344
19,555 Added 3.38%
597,581 $6.27 Million
Q4 2020

Feb 11, 2021

SELL
$11.79 - $18.94 $146,089 - $234,685
-12,391 Reduced 2.1%
578,026 $9.79 Million
Q3 2020

Nov 16, 2020

BUY
$10.34 - $15.2 $3.93 Million - $5.78 Million
380,366 Added 181.08%
590,417 $7.58 Million
Q2 2020

Aug 14, 2020

BUY
$7.81 - $17.0 $1.08 Million - $2.36 Million
138,823 Added 194.9%
210,051 $2.97 Million
Q1 2020

May 14, 2020

BUY
$5.42 - $17.75 $22,216 - $72,757
4,099 Added 6.11%
71,228 $655,000
Q4 2019

Feb 14, 2020

BUY
$5.84 - $14.9 $98,520 - $251,363
16,870 Added 33.57%
67,129 $1 Million
Q3 2019

Nov 13, 2019

BUY
$6.83 - $13.0 $135,309 - $257,543
19,811 Added 65.07%
50,259 $343,000
Q2 2019

Aug 13, 2019

BUY
$2.3 - $13.79 $70,030 - $419,877
30,448 New
30,448 $368,000

Others Institutions Holding PRVB

# of Institutions
1
Shares Held
170K
Call Options Held
0
Put Options Held
0

About Provention Bio, Inc.


  • Ticker PRVB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 81,549,904
  • Description
  • Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...
More about PRVB
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.